Merz licenses TAU Alzheimer's drug

Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

By YONI TEITZ
July 11, 2007 08:37

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Tel Aviv University has licensed an Alzheimer's treatment it developed to Merz Pharmaceuticals, a German producer of Alzheimer's drugs. Ramot, Tel Aviv University's technology transfer company, raised $8.5 million for research into the treatment in 2003. Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS